According to the Wall Street Journal, CVS will defend its acquisition of insurer Aetna in two high-profile settings Tuesday, June 4, seeking to sell a federal judge on the nearly US$70 billion deal.
CVS lawyers will be in a DC, federal court for the start of a three-day proceeding in which US District Judge Richard Leon is considering whether the Justice Department adequately protected competition when it approved the deal last year.
The deal, reached in November, combined CVS’s sprawling network of pharmacies and pharmacy-benefit-management business with Aetna’s health-plan assets.
The Justice Department’s Antitrust Division approved the merger after the companies agreed to sell off Aetna’s Medicare Part D drug business to WellCare Health Plans. The Department stated the divestiture was needed because Aetna and CVS had been important competitors in selling Medicare drug plans to seniors in 22 states.
Groups like the American Medical Association claimed the divestiture didn’t do enough to protect competition for prescription-drug plans, and they argued the Department didn’t address broader concerns about healthcare industry consolidation.
The criticism caught the attention of Judge Leon, who is considering whether to approve the settlement between the companies and the Justice Department.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas